Tratamiento sustitutivo renal y toma de decisiones compartidas

Enfermedad renal crónica; Tratamiento sustitutivo renal; Toma de decisiones compartidasMalaltia renal crònica; Tractament substitutiu renal; Presa de decisions compartidesChronic renal disease; Renal replacement treatment; Shared decision makingEl proyecto Decisiones Compartidas en Cataluña es una iniciativa de la Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) y del Consell Consultiu de pacients del Departament de Salut de la Generalitat de Catalunya. El objetivo de la misma es facilitar a las personas sanas o enfermas herramientas de información para decidir, conjuntamente con el profesional sanitario, qué intervenciones médicas, en base a la evidencia científica, son mejores según sus preferencias y valores

Malaltia renal crònica avançada: opcions de tractament

Malaltia renal crònica; Tractament de malaltiesEnfermedad renal crónica; Tratamiento de enfermedadesChronic kidney disease; Disease treatmentAquest document s’adreça a totes les persones que pateixen malaltia renal crònica en fase avançada i als seus familiars, amb la finalitat de fer més entenedora la malaltia i de ser d’ajuda per triar, juntament amb l’equip mèdic de nefrologia, el tractament substitutiu renal més adequat en cada cas

Malaltia renal crònica avançada: opcions de tractament

Malaltia renal crònica; Tractament de malaltiesEnfermedad renal crónica; Tratamiento de enfermedadesChronic kidney disease; Disease treatmentMongràfic sobre la malaltia renal crònica en fase avançada i el seu tractament

Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis.

BACKGROUND:Calprotectin is produced by neutrophils and macrophages, and released during the acute phase of the ANCA vasculitis. The aim of our study was to determine if serum and urine calprotectin are disease activity and prognosis biomarkers in ANCA vasculitis patients during remission. METHODS:Forty-two ANCA vasculitis patients were included. Twenty-seven patients were in remission phase under immunosuppressive therapy, and 15 patients were in the acute phase. Four healthy controls were included. We determined calprotectin in serum and urine samples at the time of the inclusion. We recorded the incidence of relapse and the evolution of GFR, proteinuria, hematuria, and C reactive protein and ANCA titer during 24 months of follow-up. RESULTS:In remission phase, serum calprotectin was higher than in healthy controls but lower compared to acute patients (p = 0.05). Serum calprotectin at inclusion was higher in patients who increased proteinuria during follow-up (p = 0.04), with hematuria (p = 0.08), and with non-decreasing ANCA titer (p = 0.0019). Serum calprotectin at inclusion in stable patients who subsequently decreased GFR during follow-up was higher compared with those with a stable or improving GFR (p = 0.03). Urine calprotectin was lower in patients with sclerotic histology in remission (p = 0.03) and acute phase (p = 0.12) compared to the rest of histologies. CONCLUSIONS:Worsening of renal function, hematuria, rising proteinuria and non-decreasing ANCA correlated with higher levels of serum calprotectin at recruitment. Low urine calprotectin was found in patients with sclerotic histology. Calprotectin during remission in ANCA vasculitis may be useful to identify subclinical inflammation and worse renal prognosis patients

Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis

Background Calprotectin is produced by neutrophils and macrophages, and released during the acute phase of the ANCA vasculitis. The aim of our study was to determine if serum and urine calprotectin are disease activity and prognosis biomarkers in ANCA vasculitis patients during remission. Methods Forty-two ANCA vasculitis patients were included. Twenty-seven patients were in remission phase under immunosuppressive therapy, and 15 patients were in the acute phase. Four healthy controls were included. We determined calprotectin in serum and urine samples at the time of the inclusion. We recorded the incidence of relapse and the evolution of GFR, proteinuria, hematuria, and C reactive protein and ANCA titer during 24 months of follow-up. Results In remission phase, serum calprotectin was higher than in healthy controls but lower compared to acute patients (p = 0.05). Serum calprotectin at inclusion was higher in patients who increased proteinuria during follow-up (p = 0.04), with hematuria (p = 0.08), and with non-decreasing ANCA titer (p = 0.0019). Serum calprotectin at inclusion in stable patients who subsequently decreased GFR during follow-up was higher compared with those with a stable or improving GFR (p = 0.03). Urine calprotectin was lower in patients with sclerotic histology in remission (p = 0.03) and acute phase (p = 0.12) compared to the rest of histologies. Conclusions Worsening of renal function, hematuria, rising proteinuria and non-decreasing ANCA correlated with higher levels of serum calprotectin at recruitment. Low urine calprotectin was found in patients with sclerotic histology. Calprotectin during remission in ANCA vasculitis may be useful to identify subclinical inflammation and worse renal prognosis patients

Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis

Background Calprotectin is produced by neutrophils and macrophages, and released during the acute phase of the ANCA vasculitis. The aim of our study was to determine if serum and urine calprotectin are disease activity and prognosis biomarkers in ANCA vasculitis patients during remission. Methods Forty-two ANCA vasculitis patients were included. Twenty-seven patients were in remission phase under immunosuppressive therapy, and 15 patients were in the acute phase. Four healthy controls were included. We determined calprotectin in serum and urine samples at the time of the inclusion. We recorded the incidence of relapse and the evolution of GFR, proteinuria, hematuria, and C reactive protein and ANCA titer during 24 months of follow-up. Results In remission phase, serum calprotectin was higher than in healthy controls but lower compared to acute patients (p = 0.05). Serum calprotectin at inclusion was higher in patients who increased proteinuria during follow-up (p = 0.04), with hematuria (p = 0.08), and with non-decreasing ANCA titer (p = 0.0019). Serum calprotectin at inclusion in stable patients who subsequently decreased GFR during follow-up was higher compared with those with a stable or improving GFR (p = 0.03). Urine calprotectin was lower in patients with sclerotic histology in remission (p = 0.03) and acute phase (p = 0.12) compared to the rest of histologies. Conclusions Worsening of renal function, hematuria, rising proteinuria and non-decreasing ANCA correlated with higher levels of serum calprotectin at recruitment. Low urine calprotectin was found in patients with sclerotic histology. Calprotectin during remission in ANCA vasculitis may be useful to identify subclinical inflammation and worse renal prognosis patients